Partnering

AVEROA is a biopharmaceutical company bringing innovative solutions to people with renal diseases.

Parnerships & Collaboration

AVEROA entered into two major agreements

01

Exclusive Licence

with AKEBIA Therapeutics, Inc. [AKBA], a US-based company that granted AVEROA to develop and commercialize AVA1014 in Europe, UK, Switzerland and Turkey.

02

Research Collaboration

Research collaboration and license agreement with IDIBELL for the development of a biomarker and a new treatment for renal lithiasis.

Business Model

We enhance our product portfolio with complementary products

By identifying and in-licensing late-stage drugs that have a strong therapeutic and commercial fit with our current portfolio.

Internal Development to Maximise the innovation

By positioning products in unprecedent indications by relying on products mechanisms of action and the knowledge of renal pathologies using sophisticated tools to achieve a global therapeutic action

By a smart and adapted registration strategy to optimize the targeted indications, the road to approval and the global value of the products

By generating industrial property and ensuring market protection

Commercial partners and distributors

By developing a network of commercial partners and distributors to maximize the potential of our registered products.